rmcassleman

Selected earnings coverage of Medical Device companies from 2-2-2025 through 2-7-2026 indicate that execution is still the most critical part of successful company culture. Boston Scientific, GE Healthcare, Siemens Healthineers, and Steris all show this focus will be around in 2026 and beyond.

Investors stopped rewarding vague promises this week. They want hard numbers and actual resilience. We just saw another wave of earnings (Stryker, Thermo Fisher, Roche, Elevance, DaVita), and the message to the C-Suite is clear: Stop hiding behind "macro uncertainty" and tell us your plan. Here is the reality check from the last few days: 1. You Have to Name the Number Stryker didn't flinch. They admitted tariffs will cost them $400M  next year. But they also laid out exactly how they will...

The "wait and see" era is over. This week’s earnings calls (Jan 27–28) confirmed a fundamental shift: The market is no longer rewarding medtech companies just for growing. It is rewarding them for resilience. Check back throughout the coming weeks as I cover additional companies and the running comparison chart grows. Reach out to us directly if you have a company you'd like included: hello@allons-y.co If you’re a CEO or CFO in this space, your 2026 playbook just changed. Here are three...